Introduction
The human homologues of yeast Rad6, HHR6A and HHR6B (referred as Rad6A and Rad6B) play a fundamental role in DNA damage tolerance pathway (1) (2) (3) (4) , and the ubiquitin conjugating (UBC) activity of Rad6 is essential for this function (5, 6) . The Rad6B homologue is weakly expressed in normal breast cells but overexpressed in metastatic and chemoresistant breast carcinomas (7) (8) (9) . Constitutive overexpression of Rad6B in nontransformed human breast epithelial cells induces tumorigenesis and resistance to cisplatin and doxorubicin (7, 10, 11) .
Conversely, Rad6B silencing renders cells chemosensitive (11) , implicating the relevance of Rad6 in transformation and drug resistance, and the potential therapeutic benefit of inhibiting Rad6. We have recently reported the development of a novel Rad6-selective small molecule inhibitor SMI#9 that inhibits Rad6 UBC activity (12) . SMI#9 treatment suppresses proliferation and migration, and induces apoptosis in breast cancer cells but spares normal breast cells (12) .
However, SMI#9 has poor aqueous solubility that limits its therapeutic efficacy. Here we developed a drug delivery system that would improve its solubility and uptake.
Gold nanoparticles (GNPs) are ideal drug delivery scaffolds because they are nontoxic and nonimmunogenic (13, 14) , and have good biocompatibility and stability (15) . Surface modification allows GNPs to be readily functionalized with multiple agents including chemotherapy, oligonucleotides and proteins making them good delivery vehicles (16) Here we report the synthesis of SMI#9-tethered GNPs using a chemistry that allows intracellular release of SMI#9. SMI#9-GNPs were characterized for size and ligand conjugation, and intracellular release of conjugated SMI#9 by Fourier transform infrared spectroscopy (FTIR) and liquid chromatography coupled tandem mass spectrometry (LC-MS/MS). Intracellular uptake, localization, cytotoxicity and molecular responses to SMI#9-GNP were evaluated in triple negative breast cancer (TNBC) cells as TNBCs represent a heterogeneous disease with poor clinical outcomes and few targeted therapy options as they lack estrogen receptor, progesterone receptor and Her2/neu amplification. We analyzed the responses to conjugated and free SMI#9 in mesenchymal and basal subtypes as they represent the two major TNBC subtypes (18) . We show that the mesenchymal subtype is sensitive to SMI#9-GNP and that modified SMI#9 released from GNP acts similarly to unconjugated parent SMI#9.
Methods

Synthesis of gold nanoparticle (GNP) and conjugation of Rad6 inhibitor SMI#9 to GNP
SMI#9 was synthesized as previously described (12) . The steps for GNP and SMI#9 nanoconjugation are described in Scheme 1 (19) (20) (21) (22) (23) , and details are provided under Supplementary Materials.
Characterization of GNP and GNP-drug conjugates
SMI#9 conjugated to GNP was characterized by thermogravimetric analysis (TGA) on a SDT-Q600 Thermo-Gravity Analyser using air as the supporting gas. The air flow rate was maintained at 100 ml/min, and sample heated from 25 to 800°C at a rate of 10°C/min. GNP , k is Boltzmann constant, T is 25 °C, and D was obtained from autocorrelation function via the cumulant fitting. Atomic force microscopy (AFM) imaging was conducted using a Dimension 3100 AFM from VEECO.
AFM tapping mode in liquid was used and the nanoconjugate was deposited on mica by spin coating.
Cell survival assay
MDA-MB-231, SUM-1315, MDA-MB-468, and HCC1937 TNBC cells (ATCC) were maintained in Dulbecco's Modified Eagle's Medium (DMEM)/F-12 supplemented with 5% fetal bovine serum. Nontransformed MCF10A human breast cells were maintained in DMEM/F12 supplemented with 5% horse serum, 20 ng/ml epidermal growth factor, 10 g/ml insulin, 0.5 g/ml hydrocortisone and 0.10 g/ml cholera toxin (7). SMI#9-GNP sensitivity was assessed by trypan blue staining or MTT assay. Cells (5-7 X 10 3 ) were seeded in 96-well plates and treated with free SMI#9, SMI#9-GNP, or blank-GNP at various concentrations in triplicates for 72 h. In some cases, cells were treated singly with 0.1-10 M cisplatin or in combination with SMI#9-GNP. On the final day, medium was replaced with drug-free medium, and incubated with MTT for 2-3 h. MTT-formazan crystals were dissolved in 0.04 N HCl/isopropanol and absorbance measured at 570 nm using the Synergy 2 microplate reader. Alternately, cultures were trypsinized and cell viability was determined by trypan blue exclusion using the Biorad TC10 automatic cell counter. At least three independent experiments were performed for each cell line. 
SMI#9 and SMI#9-GNP
Acridine orange/ethidium bromide staining
Breast cancer cells (10 x 10 3 ) were seeded on cover slips and treated with vehicle, free SMI#9, blank-GNP or SMI#9-GNP for 24-48 h. Cover slips were rinsed with PBS, stained with ethidium bromide/acridine orange (each 25 g/ml), and immediately imaged with an Olympus BX40 fluorescence microscope. A minimum of six fields with at least 50 cells/field were scored for determination of dye uptake (12) , and experiments were repeated at least three times.
Mitochondrial assay
The impact of free SMI#9 or SMI#9-GNP on mitochondrial membrane potential m) on were counterstained with 4',6-diamidino-2-phenylindole (DAPI) to localize the nucleus and images were acquired with an Olympus BX40 fluorescence microscope equipped with a Sony high resolution/sensitivity camera.
Western blot and immunofluorescence analysis
Breast cancer cells treated with vehicle, free SMI#9, blank-or SMI#9-GNP (1-5 M) for 24-96 h were lysed (12) , and aliquots of lysates containing 25 g of protein were subjected to SDS-PAGE and western blot analysis of PARP-1 (Cell Signaling), Rad6 (7), LC3-I/II (Cell Signaling), p62 (Cell Signaling) and -actin (Sigma). To determine LC3 or p62 subcellular localization, control or SMI#9-GNP treated cells were fixed with methanol:acetone (1:1, v/v) and stained with anti-LC3 or anti-p62 antibody. Slides were incubated with FITC-or Texas Red-conjugated antirabbit secondary antibody, counterstained with DAPI, and analyzed by fluorescence microscopy.
Statistical analysis
Each experiment was performed in triplicate and reproduced at least three times. Data are expressed as mean ± S.D, and P <0.05 determined by Student's t-test was considered to be statistically significant.
Results
Nanoparticle synthesis and characterization
For the production of SMI#9-tethered GNPs, citrate-reduced GNPs were synthesized from HAuCl4.3H 2 0 and subsequently capped by MSA. Modified SMI#9 was attached to the MSA-GNP surface via ester bond (Scheme 1). The chemical compositions of GNP and SMI#9-GNP were determined by TGA. Figure 1A shows the TGA curves of MSA-GNP (blank-GNP) and MSA-GNP conjugated SMI#9 (SMI#9-GNP) with weight loss of 6.15% and 13%, respectively, at 800°C. The detailed calculations for loading and coverage of modified SMI#9 on MSA-GNP are provided under Supplementary data. Figure 1B shows the UV-vis spectra of GNPs before and after conjugation with modified SMI#9. The surface plasmon resonance (SPR) absorption peak of freshly prepared GNPs is 508 nm, which corresponds to GNP diameter range of 3-5 nm.
However, upon conjugation with modified SMI#9, the SPR absorption peak broadened and shifted to 524 nm, which is indicative of particle aggregation. The size of SMI#9-GNPs was also determined by TEM (Fig. 1C) and AFM ( (Fig. 2B) . These results suggest efficient uptake and rapid intracellular processing of the chemically modified SMI#9-GNP conjugates.
Cellular response to SMI#9-conjugated GNP
The (Fig. 3G) . In HCC1937 (and MDA-MB-468, data not shown) cells that are unaffected by SMI#9-GNP, the GNPs appeared to aggregate at the cell surface (Fig. 3G ). When combined with cisplatin, however, SMI#9-GNP synergistically increased cisplatin sensitivity of MDA-MB-468 and HCC1937 cells (Fig. 3F ). These data suggest that once imported into the cells, SMI#9-GNP is therapeutically active in basal subtype TNBC cells.
SMI#9-GNP sensitivity is associated with apoptosis
Since MTT assays (Fig. 3A-3D ) showed variable SMI#9-GNP induced growth inhibitory effects in the TNBC lines, we verified whether these sensitivities resulted from cytostatic or cytotoxic responses. Cells undergoing apoptosis/necrosis were detected by the differential uptake of the fluorescent DNA binding dyes acridine orange and ethidium bromide. Consistent with MTT data (Fig. 3A) , SMI#9 and SMI#9-GNP treatments triggered morphological changes consistent with apoptosis in SUM1315 cells (Fig. 4A ). Early apoptosis marked by intercalated acridine orange within fragmented DNA (27) and late stages of apoptosis marked by apoptotic body separation and presence of reddish-orange color due to acridine orange binding to fragmented DNA (28) were observed in SUM1315 cells treated with SMI#9-GNP (Fig. 4A, 4C ).
SUM1315 cells treated with blank-GNP (at amounts equivalent to 5 M SMI#9-GNP) were
minimally affected as >98% of the cells showed a green intact nuclear structure (Fig. 4A, 4C ).
Acridine orange/ethidium bromide staining of MDA-MB-231 cells showed similar SMI#9-GNP induced morphological changes (data not shown). Consistent with the MTT data (Fig. 3C ), acridine orange/ethidium bromide staining showed morphological alterations consistent with apoptosis in SMI#9-treated but not SMI#9-GNP treated, confirming SMI#9-GNP insensitivity of HCC1937 cells (Fig. 4B, 4D ).
SMI#9-GNP sensitive TNBC cells show altered mitochondrial membrane potential
Since the results of acridine orange/ethidium bromide staining showed dye uptake consistent with apoptosis in SMI#9-GNP sensitive cells, we tested whether this occurred by a mitochondrial-regulated mechanism. Alterations in mitochondrial transmembrane potential were evaluated in SUM1315 and HCC1937 cells treated with free SMI#9, blank-GNP, or SMI#9-GNP (Fig. 4E, 4F ). Overnight treatment with 1 M free SMI#9 reduced Jaggregate formation in both SUM1315 and HCC1937 cells (Fig. 4E, 4F ). Mitochondrial 
Lysosomal uptake of SMI#9-GNP
Since SUM1315 and HCC1937 breast cancer cells displayed different sensitivities to SMI#9-GNP while maintaining similar cellular sensitivities to free SMI#9, we hypothesized that these variations arose from differences in uptake rather than intracellular processing as combination with cisplatin enhanced SMI#9-GNP uptake and cisplatin sensitivity (Fig. 3F) . Internalization of nanoparticles in general is accomplished by endocytosis, transfer of cargo to early and mature endosomes, and fusion to become late endosomes/lysosomes (31) (32) (33) . Control or SMI#9-GNP treated SUM1315 or HCC1937 cells were stained with LysoSensor Green DND-189 to label the lysosomes and the presence of aggregated GNP cargo examined. LysoSensor Green DND-189 is an acidotropic dye that accumulates in intracellular acidic organelles as a result of protonation and has a fluorescence intensity that is proportional to acidity (34, 35) . SMI#9-GNP is efficiently internalized into SUM1315 cells as evidenced by the presence of GNP aggregates in lysosomes marked by the LysoSensor Green DND-189 dye (Fig. 5B) . The overlapping of lysosomes with GNP aggregates and the strong sensitivity of SUM1315 cells to SMI#9-GNP suggest potential hydrolysis of the ester bond linked SMI#9-GNP and release of conjugated SMI#9 as supported by LC-MS/MS (Fig. 2) . Although both control and SMI#9-GNP treated SUM1315 cells showed robust staining with the lysosomal marker ( Fig. 5A and 5B), formation of "acidic vesicles"
(potentially indicative of autolysosome formation, a key feature of autophagy), was observed only in SMI#9-GNP treated SUM1315 cells (compare Figs. 5A' and 5B'). In contrast, HCC1937 cells showed weak staining with LysoSensor Green (Fig. 5C and 5D ) suggesting weak acidification.
SMI#9-induced cell death is associated with PARP-1 stabilization
Since SMI#9 treatment induces apoptosis by causing mitochondrial dysfunction, we analyzed (Fig. 6B) . Treatment for 24 h with free SMI#9 but not SMI#9-GNP downregulated both LC3-I and LC3-II in MDA-MB-231 cells (Fig. 6B) . Although changes in LC3-I processing was not readily apparent in SUM1315 cells treated for 24 h with free SMI#9 or SMI#9-GNP, a dramatic increase in LC3-I to LC3-II conversion that was commensurate with PARP-1 hyperactivation was observed at 48 and 96 h of treatment (Fig. 6B ). These effects are selective for SMI#9-GNP since treatment with blank-GNP for up to 96 h produced no changes in LC-3-I/II ratios or PARP-1 activation (Fig. 6B) . p62 is degraded through the autophagy-lysosomal pathway and is mediated by interaction with LC3 (37, 38) . Concomitant with SMI#9-GNP-induced increases in LC3-I to LC3-II conversion, p62
protein steady-state levels were decreased confirming autophagy induction ( Fig. 1 in Supplementary Results). Consistent with these data, LC3-positive dots were detected by immunofluorescence staining only in SMI#9-GNP treated SUM1315 cells (Fig. 6D, arrow) , whereas strongly stained p62-positive bodies were detected in control cells but not in SMI#9-GNP treated cells (Fig. 6E) . The coincident increases in PARP-1 hyperactivation, LC-I to LC3-II conversion, and p62 decrease in SMI#9-GNP treated cells signify cell death that is further supported by MTT assays (Fig. 3A) , phase-contrast micrographs (Figs. 3G, 6C) , and the presence of lysosome-associated acidic vesicles (Fig. 5B' , arrows) in SMI#9-GNP treated but not control cells. Rad6 steady-state levels were marginally increased in SMI#9-GNP treated cells (Fig. 6B) . Since Rad6 activity is inhibited under these conditions, these data suggest an important role for Rad6 activity in assuring survival of cancer cells.
Discussion
In this paper, we have developed a GNP-based vehicle for delivering SMI#9, and demonstrated that the tethered chemically modified SMI#9 is released from GNP and that it acts similar to the parent SMI#9. Whereas both basal and mesenchymal subtypes of TNBCs are sensitized by free (parent) SMI#9, we discovered that unlike the mesenchymal TNBC subtype Theoretical models predict the optimal diameter for GNP uptake to be ~50 nm in receptormediated endocytosis (39) (40) (41) . The larger aggregates found in HCC1937 and MDA-MB-468 cells may require more interactions to enable wrapping of membrane around the aggregates (39, 40, 42) . It should be noted that although all TNBC cells were cultured under similar conditions and with similar amounts of SMI#9-GNP, SMI#9-GNP aggregation occurred only in the basal subtype, suggesting local microenvironment involvement in particle aggregation. In summary, the mechanistic data presented here show that GNP is a suitable vehicle for delivering SMI#9 and that the chemically modified SMI#9 released from GNP functions similarly as the free parent SMI#9. Our data also show distinct differences in uptake and tolerability of SMI#9-GNP between basal and mesenchymal subtypes of TNBC cells that emanate from cell-specific microenvironment-induced effects on SMI#9-GNP aggregation.
Although the SMI#9-GNP aggregates are nontoxic, these data are significant because it illustrates how cell microenvironments can induce alterations in the physical properties of GNPdrug conjugates and influence their anti-cancer efficacies. Excessive autophagy combined with mitochondrial permeabilization promotes caspasedependent or caspase-independent apoptosis. SMI#9 induces PARP-1 stabilization/hyperactivation, which combined with mitochondrial dysfunction contributes to NAD+ and ATP depletion and necrosis.
